ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2009-03-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether treatment with a new drug called
ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who
previously have had a good response with cisplatin or carboplatin, is safe and helps to
decrease or stop tumor growth.